This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Out of public health concerns and given the current travel restrictions and lab closures worldwide because of COVID-19, the 27th International Symposium on Hepatitis C Virus and Related Viruses (HCV2020), scheduled to take place July 6 – 9, 2020 in Montreal, Canada has been postponed to July 6 - 9, 2021 and will now be delivered Virtually.



Daniel Lamarre, PhD

President and CEO
DiuTinus ImmunoTherapeutics Inc.

Dr Lamarre has completed his doctoral studies in biochemistry at the Université de Sherbrooke (Canada) and postdoctoral training in immunology at IRCM (Montreal) and Genentech (San Francisco). He then joined Boehringer Ingelheim R&D Canada, where he contributed to research programs in the areas of HIV and HCV infectious diseases. As the HCV therapeutic head, he established a leading position world-wide with the discovery of BILN 2061 (ciluprevir), the first-in-class antiprotease compound ever tested in human for the treatment of HCV infection. In 2003, he began his academic career at the Université de Montréal as full professor and co-founder of IRIC - one of the first System Biology Research Institute in Canada.  Over the last 25 years, Dr. Lamarre has made significant contributions in deciphering molecular aspects of virus-host interactions through system biology approaches focusing his research on the discovery of target-oriented broad-spectrum antiviral and innate immune regulators for the treatment of RNA virus infection. Recently, Dr. Lamarre has co-founded a US-based company to develop innovative long-lasting chimeric antigen receptor (CAR) T-cell therapies to improve survival rates of cancer subjects based on a long-lived pluripotent T stem cell-like memory subset.